Medical/Pharmaceuticals
KINS Clinic Launches BioRevive Gel Mask -- A New Approach to Acne Skin Microbiome Care, from a Singapore Acne Treatment Clinic
A three-way collaboration between KINS Clinic, ArrowBiome, and CHAKS Cosmetic
Design & Services brings next-generation acne skin microbiome science into
clinical skincare practice in Singapore.
SINGAPORE, July 20, 2026 /PRNewswire/ -- KINS Clinic
2026-07-20 11:00
4472
DIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURY
Highlights * Dimerix acquires Phase 2-ready asset, DMX-652 - with potential for rapid advancement into a Phase 2 clinical study under an open US Investigational New Drug (IND) application, with initial focus on acute kidney injury (AKI) * DMX-652 offers potential to address a significant unme...
2026-07-17 14:58
5530
Getinge Interim Report April-June 2026: Good organic growth, high profitability and strong cash flow
GOTHENBURG, Sweden, July 17, 2026 /PRNewswire/ -- "We delivered a strong quarter both financially and operationally with several important key achievements," says Mattias Perjos, President and CEO of Getinge. Sales in Acute Care Therapies increased in most product categories, and the positive ...
2026-07-17 14:45
3374
Creative Life Science Advances PIC/S GMP-Compliant Cell Therapy Materials and Manufacturing Platform
Targets Japan and Singapore as Part of Broader Asia Expansion TAIPEI, July 17, 2026 /PRNewswire/ -- BIO Asia-Taiwan 2026 opens July 16 at the Taipei Nangang Exhibition Center and runs through July 19. Creative Life Science (7837) is showcasing its upstream regenerative medicine materials, proces...
2026-07-17 14:12
4032
The HKIC Presents Stellar Annual Report and Joins Hands with Beyond Ventures to Support World-Class Ophthalmic Healthcare Flagship Projects
"Patient Capital" Nurtures Life Science Innovations: MingMed and Super Vision Featured as Selected Investment Stories in the HKIC's Annual Report HONG KONG, July 17, 2026 /PRNewswire/ -- Beyond Ventures, a Hong Kong-based venture capital firm, warmly congratulates the Hong Kong Investment Corpora...
2026-07-17 09:14
5528
Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study
* Completed enrollment of 105 patients in Phase 3 registration study of TLX591-Px (Illuccix®) for prostate cancer imaging in Japan. * The study data will be used to support a New Drug Application (NDA) for TLX591-Px in Japan. MELBOURNE, Australia and TOKYO, July 17, 2026 /PRNewswire/ -- Telix...
2026-07-17 06:00
5315
Telix Opens Australian-First Facility to Accelerate Delivery of New Cancer Treatments and Expand Sovereign Manufacturing
* First-of-its-kind facility in Australia where radiopharmaceuticals are developed, manufactured and administered to patients under one roof. * Patient care and research delivered in collaboration with the Melbourne Theranostic Innovation Centre (MTIC), led by its world-class clinical research...
2026-07-16 08:30
5469
First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
* First patients dosed in OPTIMAL-e[1] Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent's Hospital Sydney. * OPTIMAL-e will evaluate TLX597-Tx in earlier prostate cancer treatment setting, building on the OPTIMAL-PSMA[2] study which recently com...
2026-07-16 04:30
4335
Metabolon Expands Microbiome Panel to Strengthen Industry Leadership in Functional Microbiome Research
Enhanced panel screens for more than 800 microbiome-associated metabolites, giving researchers a broader view of microbial activity linked to human health, nutrition, disease, and treatment response MORRISVILLE, N.C., July 15, 2026 /PRNewswire/ -- Metabolon, Inc., the global leader in metabolomi...
2026-07-15 21:00
5137
Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada
MISSISSAUGA, ON, July 15, 2026 /PRNewswire/ -- Septa Pharmaceuticals Inc.
2026-07-15 19:00
2895
Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30
- ASC48 is a potentially first-in-class oral small molecule GIPR agonist. - ASC48 demonstrated an EC50 of 1 pM in the hGIPR cAMP activation assay, exhibiting greater potency than tirzepatide (EC50 = 3 pM) and is a selective agonist for GIPR without activity for GLP-1R and GCGR. - ASC48 demonstra...
2026-07-15 18:00
4611
Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Asthma
CHENGDU, China, July 15, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) and Harbour BioMed (HKEX: 02142) today announced thatthe National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (...
2026-07-15 18:00
4213
LumaCina Appoints Gary Bird as CEO to Accelerate Growth and Expand Global Sterile Injectables Portfolio
Executive Chair Mark Crotty to continue guiding long-term strategic direction
PERTH, Australia, July 15, 2026 /PRNewswire/ -- LumaCina,
2026-07-15 09:47
5263
Lynk Pharmaceuticals Announces Completion of Patient Enrollment in Phase III Clinical Trial of Zemprocitinib for Ankylosing Spondylitis
HANGZHOU, China and SHANGHAI and BOSTON, July 15, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that patient enrollment was completed on July 9 in the ...
2026-07-15 08:00
4533
Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
* As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated the superiority of replacing conventional pemetrexed/platinum chemotherapy with sac-TMT, with significantly prolonged PFS...
2026-07-15 08:00
5175
IMG Opens Applications for 2026 Fall Semester 'Student Journey Scholarship'
INDIANAPOLIS, July 13, 2026 /PRNewswire/ -- IMG
2026-07-13 21:00
3104
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business
* Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. * The acquired asset and expert team strengthen Servier's commitment to innovate for patients with high unmet medical ...
2026-07-13 20:30
2493
KLN Signs MOU with Advantech and YDCare to Support Digital Transformation of Hong Kong's Healthcare System
HONG KONG, July 13, 2026 /PRNewswire/ -- KLN Logistics Group Limited ('KLN'; Stock Code 0636.HK) announced that its healthcare subsidiary, KLN Medical Limited ('KLN Medical'), has signed a tripartite Memorandum of Understanding (MOU) with Advantech Co., Ltd. ('Advantech'; Stock Code 2395.TW), a g...
2026-07-13 12:19
3420
FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2026 LIFESTYLE PROGRAM IMPROVES BRAIN HEALTH AMONG OLDER ADULTS AT RISK FOR DEMENTIA ACROSS LATIN AMERICA
- LatAm-FINGERS Study Findings Confirm and Expand U.S. POINTER Trial Results - - Show Structured Dementia Risk Reduction Strategies Adaptable Across Cultures - Key Takeaways * The LatAm-FINGERS study shows lifestyle interventions adapted across Latin American cultures, health systems and commu...
2026-07-13 12:01
3182
Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB
SHANGHAI and HONG KONG, July 13, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2026-07-13 12:00
3935
Week's Top Stories
Most Reposted
Cyient, 3-GIS Partner to Help Telecom and Utility Operators Turn Network Data into Operational Control
[Picked up by 1154 media titles]
2026-11-11 22:00Royal Bank of Canada announces agreement to acquire Yarra Capital Management
[Picked up by 1143 media titles]
2026-11-09 21:00Algolia Powers Orange with AI Agents for Billing Support: NYSE Content Update
[Picked up by 1121 media titles]
2026-11-06 22:06
Cision Report Reveals the Consumer Trends Hidden Between Search, Social, and AI
[Picked up by 1109 media titles]
2026-11-09 23:00
Poppi Founders Launch Hydration Brand jetty: NYSE Content Update
[Picked up by 1083 media titles]
2026-11-10 22:17
Most Read
Home Companion Robot Mobo to Debut Globally and Open Pre-orders as AiMOGA Showcases Its Robot Family at the 2026 OMODA & JAECOO International User Summit
2026-11-07 13:49
27383
ZD Energy Unveils Overseas Smart Energy Solutions in Thailand, Leveraging Local Manufacturing and Scenario-Based Capabilities to Support the Country's Energy Transition
2026-11-06 22:12
16279
SILVERSEA MARKS HISTORIC OPENING OF THE CORMORANT AT 55 SOUTH, THE SOUTHERNMOST HOTEL ON EARTH, OFFERING A NEW GATEWAY TO ANTARCTICA
2026-11-07 01:05
15691
Algolia Powers Orange with AI Agents for Billing Support: NYSE Content Update
2026-11-06 22:06
12948